September 2021

LGC launches SARS-CoV-2 Delta Variant quality solution

LGC has released AccuPlex™ SARS-CoV-2 Variant Panel 2, further expanding its line of SARS-CoV-2 molecular quality solutions to include material for Delta variant detection and analysis.

AccuPlex SARS-CoV-2 Variant Panels offer full SARS-CoV-2 genome coverage with a focus on S-gene mutations in prominent variants of concern, with Variant Panel 2 featuring Kappa, Delta and Delta Plus. Wuhan wild type and an RNase P negative control are also included in the kit. This solution is compatible with multiple applications, including performance confirmation for existing SARS-CoV-2 molecular assays as well as SARS-CoV-2 variant genotyping or NGS assays.

LGC SeraCare’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process, quality control solutions that challenge the entire molecular test procedure, making them the preferred alternative to infectious materials.

Bharathi Anekella, Executive Vice President and General Manager, LGC Clinical Diagnostics, stated, “Emerging variants continue to be a challenge in the fight against the COVID-19 pandemic and the ability of clinical laboratories to deliver accurate patient results to ensure appropriate treatment and containment measures can be executed remains critical. We are fully committed to continued innovation of our AccuPlex solutions to respond to the evolving needs of the diagnostic community.”

To learn more about AccuPlex SARS-CoV-2 Variant Panel 2, as well as the complete line of SARS-CoV-2 Quality Solutions, please visit the LGC SeraCare website.